126 unknown. 126 Phase 1, 53 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 126 | Unknown 126 |
| Phase 2 | 53 | Unknown 53 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia INS19 CAR-T Cells - Leukemia, B-cell | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 12 | 2024-01-15 | 2024-01-17 |
| Safety and Efficacy Evaluation of Next-generation CD19-UCART CD19-UCART - Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | Phase 1 | Unknown | Bioray Laboratories | 20 | 2023-12-20 | 2023-01-27 |
| Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab Blinatumomab - Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Zhejiang University | 31 | 2023-11-16 | 2023-11-09 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 60 | 2023-07-01 | 2023-07-11 |
| CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms FCTX-CL19-1 (Tarcidomgen Kimleucel) - Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) | Phase 1 | Unknown | FamiCordTx | 6 | 2023-05-24 | 2024-09-19 |
| Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) Petiveria Alliacea Preparation, Placebo - Neoplasm, Stomach, Gastric Neoplasms Malignant | Phase 1 / Phase 2 | Unknown | Hospital Universitario San Ignacio | 82 | 2022-12-15 | 2022-10-19 |
| ThisCART19A Bridging to alloHSCT for R/R B-ALL Treatment - CAR, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2022-12-01 | 2023-01-11 |
| CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia CD5 CAR-T - T-cell Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Xuanwu Hospital, Beijing | 20 | 2022-10-25 | 2022-10-27 |
| Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies KUR-502 - NHL, Relapsed, Adult, B-cell Lymphoma | Phase 1 | Unknown | Athenex, Inc. | 36 | 2022-10-01 | 2023-05-18 |
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase I, Phase II - Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood | Phase 1 / Phase 2 | Unknown | KK Women's and Children's Hospital | 48 | 2022-07-18 | 2023-03-09 |
| CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma CD7CAR T cells - Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 24 | 2022-07-01 | 2022-07-06 |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation Venetoclax, Fludarabine, Cyclophosphamide - Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1 | Phase 1 | Unknown | Melbourne Health | 18 | 2022-06-08 | 2023-08-01 |
| SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies SENL101 - T-ALL, Lymphoma, T-Cell | Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 18 | 2022-05-01 | 2022-06-01 |
| CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia CD19-targeted Chimeric Antigen Receptor (CAR) T Cells - Acute Lymphocytic Leukemia | Phase 1 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 33 | 2022-04-28 | 2023-02-14 |
| Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) Blinatumomab for Injection - Pediatric ALL, B Cell, Minimal Residual Disease | Phase 1 | Unknown | Seoul National University Hospital | 20 | 2022-02-18 | 2022-03-08 |
| To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. Human CD19-CD22 Targeted T Cells Injection - Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Hrain Biotechnology Co., Ltd. | 18 | 2022-02-10 | 2022-02-04 |
| PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies PSB202 - Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Unknown | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 110 | 2021-11-15 | 2022-03-28 |
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL Navitoclax, Venetoclax - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Israeli Medical Association | 48 | 2021-10-01 | 2021-09-23 |
Showing 20 of 126. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (69) · Leukemia, Lymphocytic, Chronic, B-Cell (45) · Lymphoma, Non-Hodgkin (24) · Lymphoma, B-Cell (23) · Leukemia, B-Cell (22) · Lymphoma (22) · Lymphoma, Large B-Cell, Diffuse (20) · Leukemia, Myeloid, Acute (17) · Lymphoma, Follicular (17) · Lymphoma, Mantle-Cell (17) · Recurrence (15) · Burkitt Lymphoma (14) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (14) · Leukemia (11) · Lymphoma, B-Cell, Marginal Zone (9)
Hematologic Diseases (126) · Hemic and Lymphatic Diseases (126) · Immune System Diseases (126) · Immunoproliferative Disorders (126) · Lymphatic Diseases (126) · Neoplasms by Histologic Type (126) · Lymphoproliferative Disorders (125) · Neoplasms (124) · Leukemia (115) · Pathologic Processes (61) · Pathological Conditions, Signs and Symptoms (61) · Disease Attributes (59) · Lymphoma (54) · Chronic Disease (47)
Cyclophosphamide (16) · fludarabine (12) · Immunotherapy, Adoptive (9) · Antigens, CD19 (5) · Sensitivity and Specificity (4) · Alemtuzumab (3) · Cytarabine (3) · Flow Cytometry (3) · Indium (3) · Vincristine (3) · venetoclax (3) · AQ4N (2) · Cyclosporine (2) · Doxorubicin (2) · Drug Therapy (2)
Chinese PLA General Hospital (7) · Chongqing Precision Biotech Co., Ltd (5) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (5) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (5) · Wuhan Sian Medical Technology Co., Ltd (4) · iCell Gene Therapeutics (4) · Hebei Senlang Biotechnology Inc., Ltd. (3) · Kai Lin Xu; Jun Nian Zheng (3) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (3) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Hrain Biotechnology Co., Ltd. (2) · Jonsson Comprehensive Cancer Center (2) · National University Hospital, Singapore (2) · Novacea (2) · Shenzhen Second People's Hospital (2)
China (72) · United States (21) · Canada (4) · Israel (3) · Russia (3) · Singapore (3) · United Kingdom (3) · Australia (2) · France (2) · Germany (2) · Italy (2) · Poland (2) · Belgium (1) · Colombia (1) · Hungary (1)
Cheng Qian, PhD (4) · Heng Mei, M.D., Ph.D (3) · Gerald L. DeNardo, MD (2) · Hongyu Zhang, MD/PhD (2) · Lin Yang, Ph.D. (2) · Sanbin Wang, MD (2) · YU HU, M.D., Ph.D (2) · Alessandro Rambaldi, MD (1) · Alireza Eishi, Med student (1) · Allen Yeoh, M.D (1) · Carlos Ramos, MD (1) · Carolyn Britten, MD (1) · Chevallier Patrice, MD (1) · Chitra Hosing (1) · Chunji Gao, Professor (1)
PMID 34515338, PMID 40195173, PMID 28054442, PMID 35126471, PMID 35799791, PMID 10632319, PMID 15016963, PMID 16564913, PMID 18616528, PMID 18794884, PMID 20371346, PMID 20626398, PMID 20959411, PMID 22589701, PMID 24311149, PMID 24450857, PMID 24450858, PMID 24497570, PMID 24615776, PMID 24615777, PMID 24641416, PMID 25444722, PMID 25621950, PMID 25631767, PMID 25682597, PMID 25805929, PMID 25983002, PMID 26687796, PMID 26819050, PMID 27347147, PMID 27579615, PMID 27916294, PMID 28039295, PMID 28161329, PMID 28412099, PMID 28415728, PMID 29263894, PMID 29506548, PMID 30187944, PMID 30696950, PMID 30773077, PMID 30843659, PMID 31409768, PMID 31432232, PMID 31739095, PMID 31819192, PMID 32245502, PMID 32711004, PMID 32772769, PMID 33067379
2014 (1), 2016 (1), P30CA016672 (1), P30CA060553 (1)